Hydrogen Sulfide Reduces Heart Fibrosis in Mice Studies
Researchers find that hydrogen sulfide exposure helps attenuate cardiac fibrosis by modulating protein activity in subjects.
Updated on Oct. 16, 2026 in Heart Disease
A new study indicates that hydrogen sulfide effectively reduces cardiac fibrosis following myocardial infarction in mice models. The treatment improved overall cardiac function and inhibited key proteins responsible for tissue scarring.
Why it matters
Hydrogen sulfide functions as an endogenous gasotransmitter with potential for treating cardiac fibrosis. This finding highlights a mechanism where sulfur compounds can counteract protein expressions that lead to heart tissue damage.
The treatment with NaHS demonstrated a reduction in fibrosis-related proteins including COL-I, COL-III, CTGF, α-SMA, and MMP-9. Researchers observed these changes in a controlled laboratory environment.
The details
The study reveals that NaHS increases SENP1 S-sulfhydration, which modulates TEAD1 SUMOylation and inhibits the co-localization of TEAD1 and YAP proteins. When SENP1 was knocked down or TEAD1 was overexpressed, the protective effects of NaHS were reversed, confirming the specific pathways involved.
Timeline
October 16, 2026: The research findings were published online.
The Big Picture
This study advances the ongoing investigation into gasotransmitter-based cardiac therapies by identifying specific molecular pathways for heart tissue repair. It clarifies how sulfur-based compounds function as signaling molecules to influence cellular health after cardiac injury.
This preclinical discovery offers a foundation for future cardiac therapies but does not change current medical treatment protocols for patients. Individuals managing heart conditions should continue to follow established clinical guidelines provided by their physicians.
The takeaway
Understanding how gasotransmitters like hydrogen sulfide modulate protein activity provides a new theoretical path for managing heart tissue scarring. Future research will need to determine if these molecular benefits can be safely replicated in human clinical trials.
Further reading
For more information on current treatment trends, visit our Heart Disease section.
Source note: This article includes information reported by Nature.
